Ledraxen

Enoxaparin Sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile solution for subcutaneous or intravenous use. It is employed to prevent and treat venous thromboembolism in adult patients at risk of clot formation.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ledraxen, a low molecular weight heparin, is used in several thrombo‑embolic conditions to inhibit clot propagation.

- Deep vein thrombosis: prevents clot extension and recurrence in at‑risk patients. - Pulmonary embolism: treats existing emboli and reduces the risk of new events. - Acute coronary syndrome: provides anticoagulation during the acute phase to limit thrombus growth.

Adverse reactions may occur with any anticoagulant therapy. Monitoring for signs of bleeding and other events is essential.

Common Side Effects: - Injection site bruising or pain. - Minor gastrointestinal upset. - Mild headache. - Transient rise in liver enzymes. - Nausea.

Serious or Rare Side Effects: - Major bleeding (intracranial, gastrointestinal, or surgical sites). - Thrombocytopenia, including heparin‑induced thrombocytopenia (HIT). - Allergic reactions such as rash, pruritus, or anaphylaxis. - Elevated serum transaminases indicating liver injury. - Spontaneous hematoma formation.

Use Ledraxen only under medical supervision with appropriate laboratory monitoring.

- Renal impairment: adjust dose or avoid in severe dysfunction. - History of heparin‑induced thrombocytopenia: contraindicated. - Concomitant antiplatelet or NSAID therapy: increase bleeding risk. - Upcoming surgery or invasive procedures: discontinue as advised by clinician. - Pregnancy and breastfeeding: safety not established; weigh risks and benefits. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin may interact with several drug classes, altering anticoagulant effect or bleeding risk.

Major Interactions (Avoid): - Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants). - High‑dose aspirin or other potent antiplatelet agents. - Systemic thrombolytics (e.g., alteplase).

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs) increasing minor bleeding. - Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents. - Certain antibiotics (e.g., fluoroquinolones) that may affect platelet function.